-+ 0.00%
-+ 0.00%
-+ 0.00%
Bristol-Myers Squibb has released the first batch of clinical data from two phase III studies on KarXT in treating Alzheimer's disease-related mental illness. In both studies, KARXT showed good tolerability, and no new safety signals were found.
Share
Listen to the news
Bristol-Myers Squibb has released the first batch of clinical data from two phase III studies on KarXT in treating Alzheimer's disease-related mental illness. In both studies, KARXT showed good tolerability, and no new safety signals were found.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending